Columbia Trust Co 01012016 Acquires 480 Shares of Edwards Lifesciences Co. (NYSE:EW)

Columbia Trust Co 01012016 increased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 3.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,608 shares of the medical research company’s stock after acquiring an additional 480 shares during the period. Edwards Lifesciences makes up 1.0% of Columbia Trust Co 01012016’s investment portfolio, making the stock its 23rd largest holding. Columbia Trust Co 01012016’s holdings in Edwards Lifesciences were worth $1,880,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of EW. Paloma Partners Management Co boosted its stake in Edwards Lifesciences by 31.8% during the first quarter. Paloma Partners Management Co now owns 5,685 shares of the medical research company’s stock worth $475,000 after acquiring an additional 1,373 shares in the last quarter. 180 Wealth Advisors LLC raised its holdings in Edwards Lifesciences by 110.9% in the first quarter. 180 Wealth Advisors LLC now owns 9,544 shares of the medical research company’s stock worth $899,000 after buying an additional 5,019 shares during the last quarter. Columbia Asset Management raised its holdings in Edwards Lifesciences by 13.1% in the first quarter. Columbia Asset Management now owns 3,020 shares of the medical research company’s stock worth $253,000 after buying an additional 350 shares during the last quarter. Rehmann Capital Advisory Group raised its holdings in Edwards Lifesciences by 2.5% in the first quarter. Rehmann Capital Advisory Group now owns 9,953 shares of the medical research company’s stock worth $832,000 after buying an additional 245 shares during the last quarter. Finally, Advisory Services Network LLC raised its holdings in Edwards Lifesciences by 4.9% in the first quarter. Advisory Services Network LLC now owns 41,333 shares of the medical research company’s stock worth $3,457,000 after buying an additional 1,940 shares during the last quarter. 80.60% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE EW opened at $114.49 on Thursday. The firm has a 50 day moving average of $115.34 and a 200 day moving average of $109.68. The company has a current ratio of 3.64, a quick ratio of 2.87 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $71.48 billion, a price-to-earnings ratio of 48.72, a price-to-earnings-growth ratio of 3.69 and a beta of 1.01. Edwards Lifesciences Co. has a 12-month low of $78.44 and a 12-month high of $123.27.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Wednesday, October 27th. The medical research company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.53 by $0.01. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.32 billion. Edwards Lifesciences had a net margin of 29.00% and a return on equity of 28.13%. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.51 earnings per share. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.27 EPS for the current year.

In related news, CEO Michael A. Mussallem sold 32,550 shares of the company’s stock in a transaction on Friday, October 1st. The shares were sold at an average price of $111.72, for a total transaction of $3,636,486.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Nicholas J. Valeriani bought 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 24th. The shares were bought at an average price of $112.23 per share, with a total value of $168,345.00. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 146,351 shares of company stock valued at $16,970,864. Company insiders own 1.35% of the company’s stock.

Several research analysts have issued reports on the stock. Wells Fargo & Company lifted their target price on shares of Edwards Lifesciences from $115.00 to $126.00 and gave the stock an “equal weight” rating in a report on Thursday, October 28th. Citigroup lifted their target price on shares of Edwards Lifesciences from $113.00 to $120.00 and gave the stock a “neutral” rating in a report on Thursday, October 28th. Canaccord Genuity lifted their target price on shares of Edwards Lifesciences from $103.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, July 30th. Stifel Nicolaus boosted their price objective on shares of Edwards Lifesciences from $103.00 to $120.00 and gave the company a “buy” rating in a report on Friday, July 30th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Edwards Lifesciences from $84.00 to $113.00 and gave the company a “hold” rating in a report on Friday, July 30th. Nine research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $117.84.

About Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques.

Featured Story: Special Purpose Acquisition Company (SPAC)

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.